Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
**Background:** Recent evidence suggests that integrase strand transfer inhibitors are associated with greater weight gain than protease inhibitors in patients with human immunodeficiency virus (HIV-1). **Objectives:** To describe demographic and clinical characteristics of insured patients with HI...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2021-06-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.24535 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860269555646464 |
|---|---|
| author | Bruno Emond Carmine Rossi Aurélie Côté-Sergent Keith Dunn Patrick Lefebvre Marie-Hélène Lafeuille Prina Donga |
| author_facet | Bruno Emond Carmine Rossi Aurélie Côté-Sergent Keith Dunn Patrick Lefebvre Marie-Hélène Lafeuille Prina Donga |
| author_sort | Bruno Emond |
| collection | DOAJ |
| description | **Background:** Recent evidence suggests that integrase strand transfer inhibitors are associated with greater weight gain than protease inhibitors in patients with human immunodeficiency virus (HIV-1).
**Objectives:** To describe demographic and clinical characteristics of insured patients with HIV-1 in the United States initiating darunavir/​cobicistat/​emtricitabine/​tenofovir alafenamide (DRV/c/FTC/TAF) or bictegravir/FTC/TAF (BIC/FTC/TAF), assess the differences in weight and body mass index (BMI) change between cohorts up to one year after treatment initiation, and identify the predictors of weight gain associated with each treatment.
**Methods:** The Symphony Health, IDV® database (July 17, 2017 – September 30, 2019) was used to identify treatment naïve or virologically suppressed stable switchers who initiated DRV/c/FTC/TAF or BIC/FTC/TAF (index date) on or after July 17, 2018, were ≥18 years of age on the index date, and had ≥12 months of continuous clinical activity pre-index (baseline period). To account for differences in baseline characteristics, inverse-probability of treatment weighting (IPTW) was used. Mean weight and BMI change from pre- to post-index measurements were compared between weighted cohorts at 3, 6, 9, and 12 months post-index using mean differences. Predictors of weight or BMI gain ≥5% were evaluated at last measurement, for each treatment cohort separately.
**Results:** After IPTW, 452 and 497 patients were included in the DRV/c/FTC/TAF and BIC/FTC/TAF cohorts, respectively. Baseline characteristics were generally well-balanced (mean age=\~50 years, female: \~30%), except for the type of antiretroviral therapy from which patients switched. Patients initiated on BIC/FTC/TAF experienced greater weight and BMI increases between the pre-index period and each measurement of the post-index period than patients initiated on DRV/c/FTC/TAF, although results were only statistically significant at 9 months post-index (weight: mean difference=2.50 kg, *P*=0.005; BMI: mean difference=0.66 kg/m^2^, *P*=0.027). A common predictor of weight or BMI gain ≥5% among patients in both cohorts was female gender (DRV/c/FTC/TAF: odds ratio \[OR\]=5.92, *P*=0.014; BIC/FTC/TAF: OR=2.00, *P*\<0.001).
**Conclusion:** Patients in the BIC/FTC/TAF cohort experienced greater weight and BMI increases than patients in the DRV/c/FTC/TAF cohort, with differences reaching statistical significance at 9 months post-index. Weight gain is an important factor to consider when selecting antiretroviral regimens, since it is associated with long-term health consequences. Future studies with larger sample size and longer follow-up time are warranted. |
| format | Article |
| id | doaj-art-39e06cc1be304f26815230b3308e7ce9 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2021-06-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-39e06cc1be304f26815230b3308e7ce92025-02-10T16:13:17ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362021-06-0181Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective StudyBruno EmondCarmine RossiAurélie Côté-SergentKeith DunnPatrick LefebvreMarie-Hélène LafeuillePrina Donga**Background:** Recent evidence suggests that integrase strand transfer inhibitors are associated with greater weight gain than protease inhibitors in patients with human immunodeficiency virus (HIV-1). **Objectives:** To describe demographic and clinical characteristics of insured patients with HIV-1 in the United States initiating darunavir/​cobicistat/​emtricitabine/​tenofovir alafenamide (DRV/c/FTC/TAF) or bictegravir/FTC/TAF (BIC/FTC/TAF), assess the differences in weight and body mass index (BMI) change between cohorts up to one year after treatment initiation, and identify the predictors of weight gain associated with each treatment. **Methods:** The Symphony Health, IDV® database (July 17, 2017 – September 30, 2019) was used to identify treatment naïve or virologically suppressed stable switchers who initiated DRV/c/FTC/TAF or BIC/FTC/TAF (index date) on or after July 17, 2018, were ≥18 years of age on the index date, and had ≥12 months of continuous clinical activity pre-index (baseline period). To account for differences in baseline characteristics, inverse-probability of treatment weighting (IPTW) was used. Mean weight and BMI change from pre- to post-index measurements were compared between weighted cohorts at 3, 6, 9, and 12 months post-index using mean differences. Predictors of weight or BMI gain ≥5% were evaluated at last measurement, for each treatment cohort separately. **Results:** After IPTW, 452 and 497 patients were included in the DRV/c/FTC/TAF and BIC/FTC/TAF cohorts, respectively. Baseline characteristics were generally well-balanced (mean age=\~50 years, female: \~30%), except for the type of antiretroviral therapy from which patients switched. Patients initiated on BIC/FTC/TAF experienced greater weight and BMI increases between the pre-index period and each measurement of the post-index period than patients initiated on DRV/c/FTC/TAF, although results were only statistically significant at 9 months post-index (weight: mean difference=2.50 kg, *P*=0.005; BMI: mean difference=0.66 kg/m^2^, *P*=0.027). A common predictor of weight or BMI gain ≥5% among patients in both cohorts was female gender (DRV/c/FTC/TAF: odds ratio \[OR\]=5.92, *P*=0.014; BIC/FTC/TAF: OR=2.00, *P*\<0.001). **Conclusion:** Patients in the BIC/FTC/TAF cohort experienced greater weight and BMI increases than patients in the DRV/c/FTC/TAF cohort, with differences reaching statistical significance at 9 months post-index. Weight gain is an important factor to consider when selecting antiretroviral regimens, since it is associated with long-term health consequences. Future studies with larger sample size and longer follow-up time are warranted.https://doi.org/10.36469/001c.24535 |
| spellingShingle | Bruno Emond Carmine Rossi Aurélie Côté-Sergent Keith Dunn Patrick Lefebvre Marie-Hélène Lafeuille Prina Donga Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study Journal of Health Economics and Outcomes Research |
| title | Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study |
| title_full | Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study |
| title_fullStr | Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study |
| title_full_unstemmed | Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study |
| title_short | Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study |
| title_sort | weight change and predictors of weight change among patients initiated on darunavir cobicistat emtricitabine tenofovir alafenamide or bictegravir emtricitabine tenofovir alafenamide a real world retrospective study |
| url | https://doi.org/10.36469/001c.24535 |
| work_keys_str_mv | AT brunoemond weightchangeandpredictorsofweightchangeamongpatientsinitiatedondarunavircobicistatemtricitabinetenofoviralafenamideorbictegraviremtricitabinetenofoviralafenamidearealworldretrospectivestudy AT carminerossi weightchangeandpredictorsofweightchangeamongpatientsinitiatedondarunavircobicistatemtricitabinetenofoviralafenamideorbictegraviremtricitabinetenofoviralafenamidearealworldretrospectivestudy AT aureliecotesergent weightchangeandpredictorsofweightchangeamongpatientsinitiatedondarunavircobicistatemtricitabinetenofoviralafenamideorbictegraviremtricitabinetenofoviralafenamidearealworldretrospectivestudy AT keithdunn weightchangeandpredictorsofweightchangeamongpatientsinitiatedondarunavircobicistatemtricitabinetenofoviralafenamideorbictegraviremtricitabinetenofoviralafenamidearealworldretrospectivestudy AT patricklefebvre weightchangeandpredictorsofweightchangeamongpatientsinitiatedondarunavircobicistatemtricitabinetenofoviralafenamideorbictegraviremtricitabinetenofoviralafenamidearealworldretrospectivestudy AT mariehelenelafeuille weightchangeandpredictorsofweightchangeamongpatientsinitiatedondarunavircobicistatemtricitabinetenofoviralafenamideorbictegraviremtricitabinetenofoviralafenamidearealworldretrospectivestudy AT prinadonga weightchangeandpredictorsofweightchangeamongpatientsinitiatedondarunavircobicistatemtricitabinetenofoviralafenamideorbictegraviremtricitabinetenofoviralafenamidearealworldretrospectivestudy |